Background Contrast-enhanced mammography (CEM) is an emerging modality that generates low-energy (LE) images that are visually equivalent to full-field digital mammography (FFDM) and recombined images that show lesion vascularity such as MRI. Supplemental whole-breast US increases cancer detection rates when performed with FFDM but not with MRI. Purpose To compare the performance of CEM, LE images, and LE images supplemented with whole-breast US in breast cancer detection during screening. Materials and Methods This prospective study recruited female participants from December 2014 to February 2019 who were scheduled for screening mammography and whole-breast US. CEM (including LE images and recombined images) and whole-breast US images were interpreted by separate breast radiologists blinded to the findings on images from the other modality. Statistical differences in sensitivity and specificity, positive predictive value (PPV), negative predictive value, and abnormal interpretation rate were assessed. Biopsy recommendation rate and PPVs of biopsies performed (PPV) were calculated at the lesion level. Results Across 468 participants (median age, 54 years [IQR, 48-59 years]; all female participants), nine screen-detected cancers were diagnosed in eight participants: one cancer was depicted at LE imaging alone (cancer detection rate, 2.1 of 1000), four were depicted at LE imaging with whole-breast US (cancer detection rate, 8.5 of 1000), and eight were depicted at CEM (cancer detection rate, 17.1 of 1000; < .05). The abnormal interpretation rate was 10.3% (48 of 468) for LE images, 13.7% (64 of 468) for LE images with whole-breast US, and 18.6% (87 of 468) for CEM ( < .001). The biopsy recommendation rate was 15.0 of 1000 for LE images, 38.4 of 1000 for LE images with whole-breast US, and 42.7 of 1000 for CEM. Seven biopsies were recommended based on LE images (PPV of one of seven [14.3%]), 18 biopsies based on LE images with whole-breast US (with a PPV of five of 18 [27.8%]), and 20 biopsies based on CEM (PPV of 9 of 20 [45.0%]). Conclusion Breast cancer detection improved with CEM compared with LE images alone or LE images with whole-breast US. ClinicalTrials.gov Identifier: NCT02310698 © RSNA, 2025
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1148/radiol.242006 | DOI Listing |
Ann Oncol
February 2025
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address:
Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer.
Materials And Methods: We derived population data and death certificates for all cancers and major sites for the EU, France, Germany, Italy, Poland, Spain, and the UK since 1970, from the World Health Organization and United Nations databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment.
Acad Radiol
March 2025
Department of Nuclear Medicine, Beijing Luhe Hospital, Capital Medical University, Xinhua Road 82, Tong Zhou District, 101199 Beijing, China.
Rationale And Objectives: The objective of this research is to carry out a systematic review and meta-analysis to detect the diagnostic efficacy of 68Ga-FAPI Positron Emission Tomography (PET) Computed Tomography/Magnetic Resonance (CT/MR) in total of the lesions as well as different aspects of metastasis in individuals with ovarian cancers (OC).
Materials And Methods: The PubMed, Embase, Cochrane library, and Web of Science databases were thoroughly searched until the cut-off date of July 23, 2024. The assessment of 68Ga-FAPI PET CT/MR of OC was presented by the included studies.
J Gastroenterol Hepatol
March 2025
Department of Radiology, Yunnan Cancer Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
This review provides an in-depth exploration of the evolving role of immunotherapy in gastrointestinal (GI) cancers, with a particular focus on immune checkpoint inhibitors (ICIs) and their associated predictive biomarkers. We present a detailed analysis of established biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), and the tumor microenvironment (TME), as well as emerging biomarkers, including gut microbiota and Epstein-Barr virus (EBV). The predictive value of these biomarkers in guiding clinical decision-making and optimizing immunotherapy outcomes is thoroughly discussed.
View Article and Find Full Text PDFAnal Chim Acta
May 2025
Department of Human Sciences, The Ohio State University, USA; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA. Electronic address:
Background: The imperative need for early cancer detection, which is crucial for improved survival rates in many severe cancers such as lung cancer, remains challenging due to the lack of reliable early-diagnosis technologies and robust biomarkers. To address this gap, innovative screening platforms are essential to unveil the chemical signatures of lung cancer and its treatments. It is established that the oxidative tumor environment induces alterations in host metabolic processes and influences endogenous volatile synthesis.
View Article and Find Full Text PDFJ Genet Eng Biotechnol
March 2025
Human Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Egypt.
Introduction: The fluorescence in situ hybridization (FISH) is a very important technique, as it can diagnose many genetic disorders and cancers. Molecular cytogenetic analysis (FISH) can diagnose numerical chromosome aberrations, sex chromosomes anomalies, and many genetic disorders.
Aim: With the limited number of commercially available probes that do not cover all research needs and the high prices of the commercial probes, our goal is to apply recent technologies to produce FISH probes that can accurately and sensitively diagnose genetic diseases and cancer in Egypt and establishing the inhouse production of different FISH probes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!